Indian pharma exporters now face steep new challenges. In 2025, US policy makers announced a 100% tariff on all branded or patented drugs entering the United States from October 1, . This move shocks the industry, but India’s exports are largely low-cost generics. Experts note that Indian firms supply predominantly off-patent drugs – which are currently exempt from these
Key Strategies
- Play to India’s generics and R&D strengths: Emphasize affordable off-patent drugs (exempt from tariffs) and invest in novel biotech products. Strong R&D teams (as in enzyme and probiotic development) turn ideas into unique .
- Diversify export markets: Reduce US dependence by expanding into semi-regulated regions (Africa, Latin America, Southeast Asia) and even . Targeting new markets can offset the loss of U.S. share.
- Establish a US presence: Build or partner on American manufacturing/packaging facilities. The tariff rules exempt products from companies “building” US . Many large Indian firms already operate US-based plants to avoid these .
- Strengthen quality and compliance: Meet strict US standards. The FDA is expanding unannounced inspections of overseas so robust quality systems are critical. High compliance builds trust and can even boost demand for Indian generics.
Innovation and technical expertise will be crucial. By developing efficient enzyme-based formulations or specialty compounds, firms can differentiate their products. For example, Enzyme Bioscience’s Surat facility produces “superior enzymatic goods” for , showing how research drives unique offerings. Strong R&D pipelines allow companies to stay ahead with novel solutions and cost-efficient .
At the same time, strategic adaptation is key. Exporters are accelerating sales in new and taking advantage of US-based manufacturing to escape . Adhering to FDA and other US regulatory requirements is mandatory; meeting these standards while innovating can expand market access.
In summary, Indian pharma exporters can thrive by combining their cost-competitive generics model with R&D-driven innovation. Diversifying markets and securing government and industry support will also help. With these strategies from efficient generics to novel enzyme solutions — India’s industry, led by companies like Enzyme Bioscience, can overcome high tariffs and continue serving global health .
References and Further Reading
- Trump announces 100% tariff on imports of branded or patented pharmaceuticals from October 1 — Reuters https://www.reuters.com/sustainability/boards-policy-regulation/trump-announces-100-tariff-imports-branded-or-patented-pharmaceuticals-october-1-2025-09-25/ Reuters
- About Us | Enzyme Bioscience Pvt Ltd, Surat, India — Enzyme Bioscience official site https://www.enzymebio.com/about-us Enzyme Bioscience Pvt Ltd
- Trump’s latest 100 percent tariff on pharmaceuticals: What we know — Al Jazeera https://www.aljazeera.com/news/2025/9/26/trumps-latest-100-percent-tariff-on-pharmaceuticals-what-we-know Al Jazeera
- ‘100% tariffs on pharma unless…’: Trump’s move that may hit India — Hindustan Times https://www.hindustantimes.com/india-news/100-tariffs-on-pharma-unless-exception-in-trumps-move-that-may-hit-india-101758854377040.html Hindustan Times
- Enzyme Bioscience Private Limited — enzymebio.com (product & profile site) https://www.enzymebio.com enzymebio.com
